[1] Ni W, Yuan X, Zhang Y, et al. Sociodemographic and lifestyle determinants of multimorbidity among community-dwelling older adults: findings from 346,760 SHARE participants[J]. BMC Geriatr, 2023, 23: 419. doi:10.1186/S12877-023-04128-1. [2] Xin C, Sun X, Lu L, et al. Prevalence of sarcopenia in older Chinese adults: a systematic review and meta-analysis[J]. BMJ Open, 2021, 11: e041879. doi:10.1136/bmjopen-2020-041879. [3] Makizako H, Nakai Y, Tomioka K, et al. prevalence of sarcopenia defined using the Asia Working Group for Sarcopenia criteria in Japanese community-dwelling older adults: a systematic review and meta-analysis[J]. Phys Ther Res, 2019, 22: 53-57. [4] Yuan S, Larsson SC. Epidemiology of sarcopenia: Preva-lence, risk factors, and consequences[J]. Metabolism, 2023, 144: 155533. doi:10.1016/j.metabol.2023.155533. [5] Wudhikulprapan W, Chattipakorn SC, Chattipakorn N, et al. Iron overload and programmed bone marrow cell death: Potential mechanistic insights[J]. Arch Biochem Biophys, 2024, 754: 109954. doi:10.1016/j.abb.2024.109954. [6] Berndt C, Alborzinia H, Amen VS, et al. Ferroptosis in health and disease[J]. Redox Biol, 2024, 75: 103211. doi:10.1016/j.redox.2024.103211. [7] Tang S, Fuss A, Fattahi Z, et al. Drp1 depletion protects against ferroptotic cell death by preserving mitochondrial integrity and redox homeostasis[J]. Cell Death Dis, 2024, 15: 626. doi:10.1038/S41419-024-07015-8. [8] 朱启海,张俣.低氧诱导因子-1α在肌肉减少症发病中作用机制[J]. 基础医学与临床,2025,45:1093-1097. [9] Yang H, Tian W, Zhou B. Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma[J]. Genomics, 2022, 114: 361-377. [10] Bucarey JL, Trujillo-Gonzalez I, Paules EM, et al. Myokines and their potential protective role against oxidative stress in metabolic dysfunction-associated steatotic liver disease (masld)[J]. Antioxidants (Basel), 2024, 13:1363. doi:10.3390/antiox13111363. [11] Piccolo M, Ferraro MG, Iazzetti F, et al. Insight into iron, oxidative stress and ferroptosis: therapy targets for approaching anticancer strategies[J]. Cancers (Basel), 2024, 16:1220. doi:10.3390/cancers16061220. [12] Fang Y, Chen X, Tan Q, et al. Inhibiting ferroptosis through disrupting the NCOA4-Fth1 interaction: A new mechanism of action[J]. ACS Cent Sci, 2021, 7: 980-989. [13] Miao Y, Chen Y, Xue F, et al. Contribution of ferroptosis and Gpx4′s dual functions to osteoarthritis progression[J]. EBioMedicine, 2022, 76: 103847. doi:10.1016/j.ebiom.2022.103847. [14] Liu Y, Wan Y, Jiang Y, et al. Gpx4: The hub of lipid oxidation, ferroptosis, disease and treatment[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878: 188890. doi:10.1016/j.bbcan.2023.188890. |